| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5614165 | Journal of Cardiac Failure | 2016 | 33 Pages |
Abstract
The coprimary endpoint of the DOSE trial, a linear increase in creatinine, was paradoxically associated with improved outcomes. This was driven by absence of risk attributable to WRF and a strong risk associated with IRF. These results argue against using changes in serum creatinine as a surrogate endpoint in trials of decongestive strategies.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Meredith A. MD, MSCE, Michael R. MD, Jennifer S. BA, F. Perry MD, MSCE, Chirag R. MD, PhD, Steven G. DO, MS, W.H. Wilson MD, Jeffrey M. MD, MTR,